51��Ʒ��Ƶ

The 51��Ʒ��Ƶ has launched a three-year research and development partnership with bioMérieux, a French biotech company and global leader in diagnostic solutions for infectious diseases, thanks to efforts from the University’s Office of Industry and Economic Partnerships.

For the inaugural project, a study on sequencing, researchers in 51��Ʒ��Ƶ’s Division of Clinical Microbiology and Division of Infectious Diseases will collaborate with the company’s analytical and sequencing team.

“bioMérieux is a worldwide leader in in-vitro diagnostics and testing solutions that address the health challenges posed by infectious diseases,” said Joseph Havrilla, associate vice chancellor for innovation and entrepreneurship. “Through this strategic collaboration across multiple university labs and departments, 51��Ʒ��Ƶ researchers and clinicians are excited to work with bioMérieux scientists to confront these challenges and improve patient care by developing innovative diagnostic approaches for numerous infectious diseases.”